Teva Pharmaceuticals

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

No narrative on renewables strategy in the firm's most recent reports.

No narrative on durable removals approach in the firm's most recent reports.

• EHS management system and climate change mitigation

  Teva continued implementation of its global EHS management system in 2024 across all countries of operation, with proactive compliance evaluation, EHS leading indicators, and continued promotion of a climate change mitigation and adaptation strategy according to international standards. Water management is being addressed with a scarcity-focused approach to conservation.

• Manufacturing network consolidation and plant optimization

  As part of the Pivot to Growth strategy, Teva is optimizing global generics portfolio through product discontinuation and cost-structure improvements, including closure or divestment of a significant number of manufacturing plants in recent years across the United States, Europe, Israel, Japan and India. This network consolidation reduces operational footprint and energy use across 34 finished dosage plants in 27 countries.

• Water management with scarcity focus

  Teva is placing increased attention on water management, implementing a scarcity-focused approach to water conservation to align with community needs and advance toward sustainable operations. Risk management addresses extreme weather events including floods, heatwaves, hurricanes, sea level rise and water stress.

• Manufacturing footprint consolidation

  Teva operates 34 finished dosage and packaging plants in 27 countries and 13 API production facilities, and has closed or divested a significant number of manufacturing plants in recent years as part of network optimization under the Pivot to Growth strategy. The classification of the API business and Japan business as held for sale further reduces operated emissions scope.

• EHS management system and climate adaptation

  Teva continued implementation of its global EHS management system in all countries where it operates, promoting proactive compliance, establishing EHS standards across global operations and driving continuous improvement. Teva continues to promote climate change mitigation and adaptation strategy according to international standards, with validated Science-Based Targets for GHG reductions.

• Supplier audit and supply chain management

  Teva implemented a supplier audit program to ensure suppliers meet quality and operational standards. The Company sources APIs from its own facilities plus suppliers in Europe, Asia and the Americas, and continues to strengthen its third-party operations unit to meet cost, supply security and quality targets sustainably.

• Pharmaceutical pollutants — Urban Wastewater Treatment Directive

  In November 2024, the EU adopted revisions to the Urban Wastewater Treatment Directive requiring pharmaceutical companies to pay for a majority of the costs to remove micropollutants from wastewater. This represents a new product stewardship cost lever extending Teva's environmental responsibility downstream into water treatment infrastructure.

• Supplier audit and supply chain decarbonisation

  Teva implemented a supplier audit program for its ~13 API production facilities and external suppliers in Europe, Asia and the Americas to ensure suppliers meet quality and ESG standards. The Company maintains multiple supply sources for APIs and strengthens its third-party operations unit to meet cost, supply security and quality targets sustainably.